Vimta Labs Q1 FY26 PAT climbs to Rs. 18.89 Cr
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
The company is addressing these observations comprehensively
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
Subscribe To Our Newsletter & Stay Updated